Towards in vitro models for reducing or replacing the use of animals in drug testing

被引：38

作者：

Stresser, David M. ^{[1
,2
,3
]}

Kopec, Anna K. ^{[2
,3
,4
]}

Hewitt, Philip ^{[2
,3
,5
]}

Hardwick, Rhiannon N. ^{[2
,3
,6
]}

Van Vleet, Terry R. ^{[2
,3
,7
]}

Mahalingaiah, Prathap Kumar S. ^{[2
,3
,7
]}

O'Connell, Denice ^{[2
,8
,9
]}

Jenkins, Gary J. ^{[1
,2
,10
]}

David, Rhiannon ^{[2
,3
,11
]}

Graham, Jessica ^{[2
,12
,13
,14
]}

Lee, Donna ^{[2
,9
,14
]}

Ekert, Jason ^{[2
,3
,15
]}

Fullerton, Aaron ^{[2
,3
,16
]}

Villenave, Remi ^{[2
,3
,17
]}

Bajaj, Piyush ^{[2
,3
,18
]}

Gosset, James R. ^{[2
,3
,19
]}

Ralston, Sherry L. ^{[2
,9
,20
]}

Guha, Manti ^{[2
,3
,21
]}

Amador-Arjona, Alejandro ^{[2
,3
,21
]}

Khan, Kainat ^{[2
,3
,11
]}

Agarwal, Saket ^{[2
,3
,22
]}

Hasselgren, Catrin ^{[2
,13
,23
]}

Wang, Xiaoting ^{[2
,3
,24
]}

Adams, Khary ^{[2
,9
,25
]}

Kaushik, Gaurav ^{[2
,3
,26
]}

Raczynski, Arkadiusz ^{[2
,3
,27
]}

Homan, Kimberly A. ^{[2
,3
,28
]}

机构：

[1] AbbVie, Quantitat Translat & ADME Sci, N Chicago, IL 60064 USA

[2] Int Consortium Innovat & Qual Pharmaceut Dev IQ, N Chicago, IL 60064 USA

[3] IQ Microphysiol Syst Affiliate IQ, N Chicago, IL 60064 USA

[4] Pfizer Inc, Drug Safety Res & Dev, Groton, CT USA

[5] Merck KGaA, Chem & Preclin Safety, Darmstadt, Germany

[6] Bristol Myers Squibb, Pharmaceut Candidate Optimizat, Discovery Toxicol, San Diego, CA USA

[7] AbbVie, Investigat Toxicol & Pathol, N Chicago, IL USA

[8] AbbVie, Global Anim Welf, N Chicago, IL 60064 USA

[9] IQ 3Rs Replacement Reduct Refinement Translat & P, N Chicago, IL USA

[10] IQ Translat & ADME Sci Leadership Grp TALG, N Chicago, IL USA

[11] AstraZeneca, Clin Pharmacol & Safety Sci, Cambridge, England

[12] Genentech Inc, Prod Qual & Occupat Toxicol, San Francisco, CA 94080 USA

[13] IQ DruSafe, N Chicago, IL USA

[14] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA

[15] UCB Pharma, Cambridge, MA USA

[16] Genentech Inc, Investigat Toxicol, San Francisco, CA 94080 USA

[17] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Basel, Switzerland

[18] Sanofi, Global Investigat Toxicol, Preclin Safety, Cambridge, MA USA

[19] Pfizer Inc, Pharmacokinet Dynam & Metab, Med Design, Cambridge, MA USA

[20] AbbVie, Preclin Safety, N Chicago, IL 60064 USA

[21] Incyte, Discovery Biol, Wilmington, DE USA

[22] Alnylam Pharmaceut, Investigat Toxicol, Early Dev, Cambridge, MA USA

[23] Genentech Inc, Predict Toxicol, San Francisco, CA 94080 USA

[24] Amgen Inc, Translat Safety & Bioanalyt Sci, Amgen Res, San Francisco, CA USA

[25] Incyte, Lab Anim Resources, Wilmington, DE USA

[26] Boehringer Ingelheim Pharmaceut Inc, Nonclin Drug Safety, Ridgefield, CT USA

[27] Vertex Pharmaceut Inc, Preclin Safety Assessment, Boston, MA USA

[28] Genentech Inc, Complex In Vitro Syst Grp, San Francisco, CA 94080 USA

来源：

NATURE BIOMEDICAL ENGINEERING | 2024年 / 8卷 / 08期

关键词：

MICROPHYSIOLOGICAL SYSTEMS; INDUSTRY PERSPECTIVE; CLINICAL-TRIALS; SAFETY; CONSORTIUM; CHIP; PHARMACOKINETICS; SUPPORT; UTILITY;

D O I：

10.1038/s41551-023-01154-7

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Pharmaceutical companies continue to advocate for the use of in vitro models towards the reduction of animal use in drug discovery and development while acknowledging that further advancements are needed to heighten the models' current state of readiness.

引用

页码：930 / 935

页数：6

共 50 条

[1] Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing
Pellegatti, Mario
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (09) : 1171 - 1180
[2] Reducing the use of laboratory animals
Claude, Nancy
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2009, 193 (08): : 1767 - 1772
[3] Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, Serah
Chen, Eugene C.
Cifuentes, Helen
Co, Julia Y.
Cole, Gabrielle
Graham, Jessica
Hsia, Rebecca
Kiyota, Tomomi
Klein, Jessica A.
Kroll, Katharina T.
Lopez, Lenitza M. Nieves
Norona, Leah M.
Peiris, Heshan
Potla, Ratnakar
Romero-Lopez, Monica
Roth, Julien G.
Tseng, Min
Fullerton, Aaron M.
Homan, Kimberly A.
BIOFABRICATION, 2024, 16 (04)
[4] In vitro and in vivo drug disposition of cilengitide in animals and human
Dolgos, Hugues
Freisleben, Achim
Wimmer, Elmar
Scheible, Holger
Kraetzer, Friedrich
Yamagata, Tetsuo
Gallemann, Dieter
Fluck, Markus
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (02):
[5] In vitro diagnostic testing for drug allergy in children
Saretta, Francesca
Tomei, Leonardo
Mori, Francesca
Mayorga, Cristobalina
PEDIATRIC ALLERGY AND IMMUNOLOGY, 2023, 34 (04)
[6] Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery
Ekert, Jason E.
Deakyne, Julianna
Pribul-Allen, Philippa
Terry, Rebecca
Schofield, Christopher
Jeong, Claire G.
Storey, Joanne
Mohamet, Lisa
Francis, Jo
Naidoo, Anita
Amador, Alejandro
Klein, Jean-Louis
Rowan, Wendy
SLAS DISCOVERY, 2020, 25 (10) : 1174 - 1190
[7] Recent advances in the development of in vitro liver models for hepatotoxicity testing
Lu, Siming
Zhang, Jingwei
Lin, Sha
Zheng, Danfeng
Shen, Yan
Qin, Jiale
Li, Yangyang
Wang, Shuqi
BIO-DESIGN AND MANUFACTURING, 2021, 4 (04) : 717 - 734
[8] The potential of multi-organ-on-chip models for assessment of drug disposition as alternative to animal testing
van Berlo, Damien
Steeg, Evita van de
Amirabadi, Hossein Eslami
Masereeuw, Rosalinde
CURRENT OPINION IN TOXICOLOGY, 2021, 27 : 8 - 17
[9] In vitro human tissue models - moving towards personalized regenerative medicine
Schenke-Layland, Katja
Nerem, Robert M.
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (4-5) : 195 - 196
[10] Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects
Nair, Dileep G.
Weiskirchen, Ralf
CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (01)

← 1 2 3 4 5 →